What is MiRus?
MiRus operates at the intersection of material science and clinical medicine, specializing in the development of innovative biomaterials and procedural technologies. Its core competency lies in the application of a proprietary molybdenum-rhenium alloy, which offers superior strength and durability compared to traditional medical-grade materials. This technological advantage allows for the creation of less invasive implants and sophisticated monitoring solutions for patients suffering from complex orthopedic, spine, and structural heart diseases.
By integrating digital health technologies with advanced implant design, MiRus is effectively addressing critical clinical challenges. The company's commitment to enhancing surgical efficiency and long-term patient outcomes has established it as a key innovator in the life sciences sector, fostering deep collaborations with healthcare professionals to redefine the standard of care across multiple medical specialties.
How much funding has MiRus raised?
MiRus has raised a total of $1.6B across 3 funding rounds:
Debt
$1M
Unspecified
$65M
Stock/Share Issuance
$1.5B
Debt (2020): $1M with participation from PPP
Unspecified (2021): $65M led by Mammoth Scientific
Stock/Share Issuance (2026): $1.5B supported by Boston Scientific
Key Investors in MiRus
Boston Scientific
Boston Scientific Corporation is a global medical device company specializing in the development, manufacture, and commercialization of minimally invasive technologies across multiple interventional specialties.
Mammoth Scientific
Mammoth Scientific is a venture-focused firm that identifies and supports high-potential medical technology companies, providing the necessary capital and strategic guidance to bring innovative healthcare solutions to market.
PPP
Public-Private Partnership
What's next for MiRus?
With the successful closure of this major strategic investment, MiRus is well-positioned to scale its manufacturing capabilities and broaden its clinical reach. The capital will likely be deployed to accelerate the regulatory approval process for its next-generation implant portfolio and to deepen its investment in digital health integration. As the company moves into this next phase of growth, the focus will remain on clinical validation and the commercialization of its proprietary alloy-based solutions.
Looking ahead, MiRus is expected to leverage its strategic partnerships to penetrate deeper into global markets, particularly in the cardiovascular and orthopedic segments. The company's ability to maintain a high-authority position in the medical technology space will depend on its continued success in translating material science breakthroughs into tangible, patient-centric clinical outcomes, thereby solidifying its role as a leader in the future of minimally invasive surgery.
